{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:16:06Z","timestamp":1788498966131,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically compare sodium-glucose linked transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i) in glycemic control, weight reduction and genital infection risk in type 2 diabetic patients, and provide evidence-based support for individualized clinical medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Web of Science, Cochrane Library, and EMBASE was performed for randomized controlled trials (RCTs) from database inception. Data on glycated hemoglobin, body weight, and genital infections were extracted. Risk of bias was assessed with the Cochrane ROB 2.0 tool. Meta-analyses were conducted using RevMan 5.4 and Stata 17.0, with effect sizes pooled by high- and low-dose SGLT2i subgroups. Subgroup analyses, sensitivity analyses, publication bias assessment (funnel plots plus Egger\u2019s test), and GRADE evidence quality rating were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      10 RCTs were ultimately included. For low-dose SGLT2i, the reduction in glycated hemoglobin was not statistically different from that of DPP4i (mean difference [MD] = 0.01%, 95% confidence interval [CI]: \u22120.05% to 0.07%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.75). In contrast, high-dose SGLT2i demonstrated superior glycemic efficacy (MD = \u22120.15%, 95% CI: \u22120.27% to \u22120.03%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.01). Regardless of dosage, SGLT2i were significantly more effective than DPP4i in reducing body weight (low-dose MD = \u22121.69, high-dose MD = \u22121.92; both\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01). Regarding safety, both low- and high-dose SGLT2i were associated with a significantly higher risk of genital infections compared with DPP4i (low-dose odds ratio [OR] = 4.25, high-dose OR\u00a0=\u00a04.03; both\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01). Subgroup analyses suggested that the glucose-lowering effects might vary among individual SGLT2i agents, but these exploratory findings should be interpreted with caution due to the limited number of studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High-dose SGLT2i offer superior glycemic control versus DPP4i; all SGLT2i doses confer significant weight loss benefits but carry a higher genital infection risk. Clinicians should therefore consider individual glycemic targets, weight status, and infection risk when selecting glucose-lowering therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD420261468619<\/jats:ext-link>\n                      , identifier CRD420261468619.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1930813","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:26:31Z","timestamp":1788495991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiancong","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Huizhou Central People\u2019s Hospital","place":["Huizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-3036-4","article-title":"Global risk factors, epidemiology, and disease burden of type 2 diabetes","volume":"69","author":"Chen","year":"2026","journal-title":"Sci China Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2024.2322107","article-title":"A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries","volume":"17","author":"Butt","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.040217","article-title":"Heterogeneity of cardiovascular effects of second-line glucose-lowering therapies in adults with type 2 diabetes across the range of moderate baseline cardiovascular risk","volume":"14","author":"Deng","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.05.069","article-title":"Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes: a multinational, federated analysis of LEGEND-T2DM","volume":"84","author":"Khera","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0733-7919","article-title":"SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"50","author":"Wang","year":"2018","journal-title":"Horm Metab Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7326\/m15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015588.pub2","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00387-4","article-title":"Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/dc14-2365","article-title":"Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes","volume":"38","author":"Lewin","year":"2015","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13473","article-title":"A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study","volume":"20","author":"Scott","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"24695","DOI":"10.1038\/s41598-024-76256-6","article-title":"Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion","volume":"14","author":"Sato","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40360-025-01055-2","article-title":"Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records","volume":"26","author":"Hayakawa","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01170-4","article-title":"Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors","volume":"21","author":"Lee","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13959","article-title":"A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection","volume":"22","author":"Fralick","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01613-7","article-title":"Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: a retrospective cohort study using a claims database","volume":"15","author":"Imai","year":"2024","journal-title":"Diabetes Ther"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:26:32Z","timestamp":1788495992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"alternative-id":["10.3389\/fendo.2026.1930813"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1930813","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1930813"}}